Immune Landscape Changes in MASLD and the Effects of 11β-HSD1 Inhibition Revealed by Single-Cell Mass Cytometry

This study aims to identify immune markers associated with metabolic dysfunction-associated steatotic liver disease (MASLD) by employing high-dimensional mass cytometry (CyTOF) to profile peripheral blood mononuclear cells (PBMCs). PBMCs were collected from healthy donors (n=6), MASLD patients (n=4), and MASLD patients treated with an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor (n=2). By comparing these groups, the study investigates disease-specific immune alterations and evaluates immune cell changes following treatment to assess the immunomodulatory potential of 11β-HSD1 inhibition in MASLD.